OR12. Augmentation of endothelial progenitor cell proliferation in stable coronary artery disease subjects using human umbilical cord blood-mesenchymal stem cell-derived secretome in hyperglycemia condition

Abstract

Abstract Background and Aims The number of endothelial progenitor cells (EPC) was decreased in stable coronary artery disease (SCAD) and diabetic patients. Human umbilical cord blood-mesenchymal stem cell-derived secretome (secretome) has the potential to improve the proliferation of EPC. This study aims to figure out the effect of the secretome on EPC proliferation of SCAD patients and hyperglycemia conditions. Method and Results EPC’s were isolated from peripheral blood samples and cultured for three days in the Stemline II medium. Cultured EPC’s were incubated with various concentrations of secretome (2%, 10%, and 20%). The other groups were treated with high glucose (25 mmol/L), a combination of secretome and high glucose, vascular endothelial growth factors-only (positive group), and the basal medium only (negative group). MTT cell proliferation assay kit was used to evaluate the EPC’s proliferation at 72 hours after reagent addition. The absorbance of MTT was measured in optical density (OD). The 20% secretome group was significantly higher than the positive control group (1.59 vs. 1.43; p < 0.001). EPC proliferation in the secretome group is dose-dependent manner. EPC’s proliferation of the high glucose group was significantly lower than the negative control group (0.65 vs. 0.89; p < 0.001). EPCs proliferation OD was significantly higher between a combination of 20% secretome and high glucose than the secretome-only group (1.78 vs. 1.59; p < 0.001). Conclusion The secretome enhances the EPC proliferation of SCAD patients, even in a high glucose condition. The secretome is a new potential substance to modulate the EPC proliferation of SCAD patients.